{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:13:21Z","timestamp":1790910801250,"version":"4.1.0"},"reference-count":0,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T00:00:00Z","timestamp":1215388800000},"content-version":"vor","delay-in-days":2744,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2001,1]]},"abstract":"<jats:p>The secretory capacity, <jats:italic>in vivo<\/jats:italic>, of clinically non\u2010functioning pituitary adenomas may possibly predict tumour volume reduction during intensive medical therapy.<\/jats:p><jats:p>Ten patients (mean (range) 53\u2003years (26\u201373)) with clinically non\u2010functioning macroadenomas, \u2265\u200310\u2003mm were studied. The secretory capacity of the adenomas was examined using basal, NaCl and TRH\u2010stimulated LH, FSH and \u03b1\u2010subunit levels. The effect on tumour volume of 6 months' therapy with the combination of a somatostatin analogue, octreotide 200 \u00b5g \u00d7 3\/day and a dopamine\u2010D2\u2010agonist, cabergoline 0\u00b75\u2003mg \u00d7 1\/day was studied. The basal LH, FSH and \u03b1\u2010subunit levels were determined before and during 6 months' therapy with octreotide and cabergoline, and MR scans were used to evaluate tumour volume before and during this period of therapy. Octopus\u2010perimetry was used to examine the visual fields.<\/jats:p><jats:p>A reduction in tumour volume (mean \u00b1 SEM (range); 30% \u00b1 4% (18\u201346%)) during 6 months of combination therapy with octreotide and cabergoline was recorded only in patients with <jats:italic>in vivo<\/jats:italic> secretory potential. Tumour volume was not reduced in four patients: in three of these patients it remained unchanged while in one patient it was observed to have increased (by 14%). Of the six patients with pretherapy secretory capacity, one displayed a very high basal level of \u03b1\u2010subunit (74 \u00b5g\/l) despite unmeasurable levels of LH and TSH, and an FSH\u2010level of 1 IU\/l. The other five patients presented paradoxical LH, FSH and\/or \u03b1\u2010subunit responses to TRH. A reduction in basal levels of LH, FSH and\/or \u03b1\u2010subunit was observed in all six patients, and the maximum reduction of at least one of the hormonal levels was 66% \u00b1 7% (50\u201398%). The basal levels of LH, FSH and \u03b1\u2010subunit in the 10 patients were (mean \u00b1 SEM (range)), 3\u00b70 IU\/l \u00b1 1\u00b70 (0\u00b70\u20137\u00b74), 12\u00b77 IU\/l \u00b1 5\u00b70 (0\u00b70\u201339\u00b70) and 9\u00b70 IU\/l \u00b1 7\u00b70 (0\u00b72\u201374\u00b70). During six months of therapy with octreotide and cabergoline, the basal levels of LH, FSH and \u03b1\u2010subunit were reduced by \u2265 50% in seven patients \u2013 including the six patients with <jats:italic>in vivo<\/jats:italic> secretion prior to therapy. No new visual field defects were detected during therapy and no deterioration of existing visual field defects was recorded. The medical therapy was well tolerated.<\/jats:p><jats:p>The <jats:italic>in vivo<\/jats:italic> basal and TRH\u2010stimulated secretory capacity of LH, FSH and \u03b1\u2010subunit predicted tumour reduction following intensive medical therapy in all of our patients with non\u2010functioning pituitary adenomas.<\/jats:p>","DOI":"10.1046\/j.1365-2265.2001.01172.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T10:47:45Z","timestamp":1047379665000},"page":"23-30","source":"Crossref","is-referenced-by-count":50,"title":["<i>In vivo<\/i> secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non\u2010functioning pituitary adenomas"],"prefix":"10.1111","volume":"54","author":[{"given":"Marianne","family":"Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Bjerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik D.","family":"Schr\u00f8der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Edal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poul F.","family":"H\u00f8ilund\u2010Carlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Hyltoft","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,7]]},"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.2001.01172.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.2001.01172.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2265.2001.01172.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T21:31:07Z","timestamp":1695850267000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2265.2001.01172.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["10.1046\/j.1365-2265.2001.01172.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2265.2001.01172.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1]]}}}